Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka, M Mizukami, Y Ichiki… - Lung Cancer, 2009 - Elsevier
BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka, M Mizukami… - Lung …, 2009 - lungcancerjournal.info
Background This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
K Sugio, H Uramoto, T Onitsuka… - Lung Cancer …, 2008 - europepmc.org
Background This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
[引用][C] Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K SUGIO - Lung Cancer, 2008 - cir.nii.ac.jp
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth
factor receptor gene mutations | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
factor receptor gene mutations | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka, M Mizukami, Y Ichiki… - Lung Cancer, 2009 - infona.pl
This study prospectively assessed the efficacy of gefitinib and the survival benefit for non-
small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) …
small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) …
[引用][C] Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K SUGIO, H URAMOTO, K YASUMOTO… - Lung …, 2009 - pascal-francis.inist.fr
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth
factor receptor gene mutations CNRS Inist Pascal-Francis CNRS Pascal and Francis …
factor receptor gene mutations CNRS Inist Pascal-Francis CNRS Pascal and Francis …
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka… - Lung cancer …, 2009 - pubmed.ncbi.nlm.nih.gov
Background This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …
[引用][C] Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations
K Sugio, H Uramoto, T Onitsuka, M Mizukami, Y Ichiki… - Lung Cancer, 2009 - cir.nii.ac.jp
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth
factor receptor gene mutations | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
factor receptor gene mutations | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …